filterwp

Cardiovascular data presented at EuroPCR 2022 demonstrates successful device performance during a TAVR procedure with no complications.  Caesarea, Israel, May 31st, 2022 – Filterlex Medical Ltd., a cardiovascular medical device startup, announced today results from a first-in-human (FIH) study demonstrating the safety, feasibility, and performance of the CAPTIS device. CAPTIS is a next-generation, full-body embolic …

Filterlex Medical Announces Positive Results from A First-In-Human Study for the CAPTIS® Full-Body Embolic Protection Device Read More »

Cardiovascular study results to be presented by Prof. Ran Kornowski, Director of the Cardiology Center, Rabin Medical Center at the EuroPCR 2022 conference in May Caesarea, Israel, May 10th, 2022 – Filterlex Medical Ltd., a cardiovascular medical device startup, announced today that it has completed its CAPTIS First-In-Human (FIH) study. Study results will be presented …

Filterlex Medical Successfully Completes First-In-Human Study for CAPTIS® Full-Body Embolic Protection Device Read More »

Equity investment to support advancement of its breakthrough full-body embolic protection device to reduce the risk of stroke and other complications during left-heart procedures. Caesarea, Israel, Dec 21st, 2021– Filterlex Medical, a cardiovascular medical device startup, announced today that it has been selected to receive €7 Million equity investment from the European Innovation Council Accelerator (EIC).  The …

Cardiovascular Startup, Filterlex Medical, Selected to Receive €7M from the European Innovation Council Read More »

Caesarea, Israel, Nov 18th, 2021– Filterlex Medical, a cardiovascular medical device startup, announced today that it has recently completed a US $6 Million series A1 investment round from leading private healthcare investors. The financing will accelerate implementation of the company’s CAPTIS® clinical program. The CAPTIS is a next-generation, full-body embolic protection device to reduce the …

Filterlex Medical Closes a $6Million Series A1 Investment to Accelerate the CAPTIS® Cardiovascular Clinical Program Read More »

€2.1M Grant to support Filterlex’s CAPTIS clinical trials Yokneam, Israel (September 16, 2019) – Filterlex Medical, an innovative medical device startup in the cardiovascular field,  today announced that the company has been selected for the Phase 2 Horizon 2020 SME Instrument program. The SME Instrument program awards financial support to companies that demonstrate world class …

The European Commission Horizon 2020 Program Backs Filterlex’s Embolic Protection Device – CAPTIS Read More »